Dr Saher Tariq completed her MSc dermatology from Cardiff university. She did her dissertation on Facial hyperpigmentation for which she reviewed 170 primary and secondary research papers and suggested diagnostic and topical treatment algorithm. Some of her work in other fields of medicine has been published in reputed journals..
Facial hyperpigmentation is a major cause of embarrassment for the patient and adversely impacts the quality of life. It is more of a concern for dark skinned individuals due to the difference in structure and function of the skin among different skin types. There are many causes of facial hyperpigmentation; their pathogenesis differs depending on the factors influencing melanogenesis. Many depigmenting agents have been used for the treatment of facial hyperpigmentation but none of them has proven to be effective and safe for long term treatment. Hydroquinone has been used as gold standard treatment for facial hyperpigmentation for decades. Due to a concern regarding its long term safety, there is interest in developing new milder yet effective natural depigmenting agents. The aim of this poster is to provide an overview of the common acquired causes of facial hyperpigmentation and topical treatment options available. A comprehensive search was done on different scientific search engines, using facial hyperpigmentation as search key words. The plethora of existing treatment can be broadly divided into topical treatment and no- topical treatment. The emphasis in this study is on topical treatment. Common topical depigmenting agents have been used for decades and are well studied, however their long term safety is a concern. On the other hand alternative topical depigmenting agents are thought to be safe. However, lack of comparative studies with standard treatment (hydroquinone) and many gaps in literature has been identified. A multimodal diagnostic and treatment algorithm is proposed to guide clinicians on management of facial hyperpigmentation.
Dr Pooja Kadam, Dermatology and Phlebology Research Fellow from Sydney, Australia. She completed MBBS from the University of New South Wales in 2011 and currently pursuing her Master of Science (Medicine) through research. She have spent a year doing general medicine residency in Albany, New York. Currently She is also the unaccredited dermatology registrar at St Vincent's Hospital, Sydney and assist with the dermatology outpatient’s clinics. Her aim is to secure a position in Dermatology training in Sydney.
An 89 year old female presented with an eighteen-‐month history of a large, protuberant, non-‐tender left groin mass measuring15x8 cms (Fig1, black arrow). There were numerous melanocytic nevi present on her chest and abdomen. Past medical history was unremarkable. Computed Tomography (CT) of the pelvis showed a heterogeneously enhancing well-‐circumscribed complex mass in the subcutaneous tissue with mixed solid and cystic components. Core biopsy was performed and histopathological analysis revealed scattered dissociated malignant cells with enlarged, eccentric nuclei and unevenly distributed chromatin, consistent with metastatic melanoma. A staging CT revealed bilateral lower lobe pulmonarymetastasis with left hilar lymphadenopathy. The primary site of the melanoma remains to be established. The patient declined any treatment and died within six months of diagnosis.The incidence of malignant melanoma is rising with majority of the cases being detected when the disease is curable. However a small proportion of cases present with metastatic disease at time of diagnosis and carry a poor prognosis (1,2). The 10-year survival rate for patients with metastatic melanoma is known to be less than 10% (2). Although any organ can be involved, common sites for metastases include the liver, bone and brain. Cutaneous metastases are a frequent event in the progression of melanoma seen both in the early and late phases of disease (3). The site of metastasis is an important independent predictor of survival; patients with distal nodal and soft tissue metastases have a better survival than patients with visceral metastasis (3). Systemic therapy is the cornerstone of treatment for metastatic melanoma. Palliative surgery or radiotherapy to metastatic sites is generally performed to relieve symptoms secondary to tumor growth. In summary, melanoma is a potentially fatal form of skin cancer and early detection is crucial to improve survival and decrease mortality.